<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01869686</url>
  </required_header>
  <id_info>
    <org_study_id>20120351</org_study_id>
    <nct_id>NCT01869686</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Concentration of Denosumab in Seminal Fluid in Healthy Men After a Single Subcutaneous Dose</brief_title>
  <official_title>An Open-label Study to Evaluate the Concentration of Denosumab in Seminal Fluid After a Single Subcutaneous Injection in Healthy Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1b, open-label, single dose study in healthy male subjects. Approximately 12
      healthy male subjects will receive a subcutaneous injection of denosumab on Day 1. Subjects
      will be followed by a 105 day treatment-free follow-up period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Denosumab in Seminal Fluid</measure>
    <time_frame>Days 1, 10, 22, 36, 50, 78 and 106</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Concentration (Tmax) of Denosumab in Seminal Fluid</measure>
    <time_frame>Days 1, 10, 22, 36, 50, 78 and 106</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Seminal Fluid</measure>
    <time_frame>Days 1, 10, 22, 36, 50, 78 and 106</time_frame>
    <description>The area under the denosumab seminal fluid concentration-time curve from time zero to last quantifiable concentration (AUClast), estimated using the linear trapezoidal method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Denosumab in Serum</measure>
    <time_frame>Days 1, 10, 22, 36, 50, 78 and 106</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Observed Concentration (Tmax) of Denosumab in Serum</measure>
    <time_frame>Days 1, 10, 22, 36, 50, 78 and 106</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Serum</measure>
    <time_frame>Days 1, 10, 22, 36, 50, 78 and 106</time_frame>
    <description>The area under the denosumab serum concentration-time curve from time zero to last quantifiable concentration (AUClast), estimated using the linear trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Maximum Seminal Fluid Concentration by the Serum Concentration (Cmax Ratio)</measure>
    <time_frame>Days 1, 10, 22, 36, 50, 78 and 106</time_frame>
    <description>The ratio of maximum denosumab seminal fluid concentration over the denosumab serum concentration at the corresponding time point (Cmax Ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Seminal Fluid AUC by Serum AUC for the 106 Day Dosing Period</measure>
    <time_frame>Days 1, 10, 22, 36, 50, 78 and 106</time_frame>
    <description>The ratio of denosumab seminal fluid AUC over denosumab serum AUC for the 106-day dosing period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of Denosumab Seminal Fluid Concentration Over the Denosumab Serum Concentration at the Last Study Time Point (Day 106).</measure>
    <time_frame>Day 106</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>60 mg</description>
    <arm_group_label>Denosumab</arm_group_label>
    <other_name>Prolia (R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subject has provided informed consent; Healthy male between ≥40 to ≤ 65 years of age
        (inclusive) at the time of enrollment; Subject must be willing and able to produce a semen
        sample on seven separate study visits; Subject must be willing to refrain from ejaculation
        for a 48 hour period prior to each sample collection;

        Exclusion Criteria:

        Any condition or drug therapy that might interfere with the subjects ability to ejaculate
        and produce a semen sample; Clinically significant abnormality during the screening
        physical examination, ECG, or laboratory evaluation; Known history of blood in urine or
        semen; Osteonecrosis of the jaw (ONJ) or risk factors for ONJ such as invasive dental
        procedures (eg, tooth extraction, dental implants, oral surgery in the past 6 months), poor
        oral hygiene, periodontal and/or pre-existing dental disease; Recent tooth extraction
        (within 6 months of screening visit); Evidence of hypocalcemia at screening; Known vitamin
        D deficiency; Malignancy (except non-melanoma skin cancers) within the last 5 years;
        Positive for human immunodeficiency virus (HIV) at screening or known diagnosis of AIDS;
        Positive Hepatitis B Surface Antigen (HepBsAg) (indicative of chronic Hepatitis B) or
        detectable Hepatitis C virus Ribonucleic acid (RNA) by Polymerase Chain Reaction (PCR) at
        screening (indicative of active Hepatitis C - screening is generally done by Hepatitis C
        Antibody (HepCAb), followed by Hepatitis C virus RNA by PCR if HepCAb is positive); History
        of hypersensitivity or allergic reaction to mammalian cell derived drug products or
        sensitivity to any of the products or components to be administered during dosing; Known
        intolerance to calcium or vitamin D supplements; Subject previously has entered this study
        or has been previously exposed to denosumab in the past 12 months; Has donated or lost ≥
        400 mL of blood or plasma within 8 weeks prior to screening; Positive urine screen for
        alcohol and/or potential drugs of abuse at screening unless medication is prescribed by a
        physician and approved by the Investigator and Amgen; Known alcohol abuse or use of illicit
        drugs within 12 months of enrollment; Subject is unwilling or unable to limit alcohol
        consumption throughout the course of the study. Alcohol is prohibited 24 hours prior to
        screening and administration of investigational product. Alcohol is limited to no more than
        2 drinks per day for the duration of the study; where a standard drink is equivalent to 12
        ounces of regular beer, 8-9 ounces of malt liquor, 5 ounces of wine, or 1.5 ounces of 80
        proof distilled spirits; Currently receiving treatment in another investigational device or
        drug study, or less than 30 days or 5 half-lives (whichever is longer) since ending
        treatment on another investigational device or drug study(s). Other investigational
        procedures while participating in this study are excluded; Use of any non-Amgen approved
        over-the-counter or prescription medications, within the 14 days or 5 half-lives (whichever
        is longer), prior to receiving the dose of denosumab. Acetaminophen (up to 2 g per day) for
        analgesia and hormone replacement therapy (eg, androgen, thyroid) will be allowed. Other
        medications may be approved following review by the Principal Investigator and the Amgen
        Medical Monitor. Written documentation of this review and Amgen acknowledgement is required
        for subject participation; Subject likely to not be available to complete all
        protocol-required study visits or procedures, and/or to comply with all required study
        procedures to the best of the subject and Investigator's knowledge; Subject has any kind of
        disorder that, in the opinion of the Investigator, may compromise the ability of the
        subject to give written informed consent and/or to comply with all required study
        procedures; History or evidence of any other clinically significant disorder, condition or
        disease that, in the opinion of the Investigator or Amgen physician, if consulted, would
        pose a risk to subject safety or interfere with the study evaluation, procedures or
        completion
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2013</study_first_submitted>
  <study_first_submitted_qc>May 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2013</study_first_posted>
  <results_first_submitted>September 22, 2014</results_first_submitted>
  <results_first_submitted_qc>September 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 26, 2014</results_first_posted>
  <last_update_submitted>November 5, 2014</last_update_submitted>
  <last_update_submitted_qc>November 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient enrolled 17 June 2013; last patient enrolled 17 June 2013.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Denosumab</title>
          <description>Participants received a single subcutaneous injection of 60 mg denosumab on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Denosumab</title>
          <description>Participants received a single subcutaneous injection of 60 mg denosumab on Day 1.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.6" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black (or African American)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Othe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.73" spread="4.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Concentration (Cmax) of Denosumab in Seminal Fluid</title>
        <time_frame>Days 1, 10, 22, 36, 50, 78 and 106</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>Participants received a single subcutaneous injection of 60 mg denosumab on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of Denosumab in Seminal Fluid</title>
          <population>Pharmacokinetic population</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" spread="81.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Observed Concentration (Tmax) of Denosumab in Seminal Fluid</title>
        <time_frame>Days 1, 10, 22, 36, 50, 78 and 106</time_frame>
        <population>Pharmacokinetic population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>Participants received a single subcutaneous injection of 60 mg denosumab on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Concentration (Tmax) of Denosumab in Seminal Fluid</title>
          <population>Pharmacokinetic population with available data</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" spread="81.9" lower_limit="8.0" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Seminal Fluid</title>
        <description>The area under the denosumab seminal fluid concentration-time curve from time zero to last quantifiable concentration (AUClast), estimated using the linear trapezoidal method.</description>
        <time_frame>Days 1, 10, 22, 36, 50, 78 and 106</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>Participants received a single subcutaneous injection of 60 mg denosumab on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Seminal Fluid</title>
          <description>The area under the denosumab seminal fluid concentration-time curve from time zero to last quantifiable concentration (AUClast), estimated using the linear trapezoidal method.</description>
          <population>Pharmacokinetic population</population>
          <units>days*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5220" spread="4880" lower_limit="8.0" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Concentration (Cmax) of Denosumab in Serum</title>
        <time_frame>Days 1, 10, 22, 36, 50, 78 and 106</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>Participants received a single subcutaneous injection of 60 mg denosumab on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of Denosumab in Serum</title>
          <population>Pharmacokinetic population</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6170" spread="2070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Observed Concentration (Tmax) of Denosumab in Serum</title>
        <time_frame>Days 1, 10, 22, 36, 50, 78 and 106</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>Participants received a single subcutaneous injection of 60 mg denosumab on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Observed Concentration (Tmax) of Denosumab in Serum</title>
          <population>Pharmacokinetic population</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="81.9" lower_limit="7.9" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Serum</title>
        <description>The area under the denosumab serum concentration-time curve from time zero to last quantifiable concentration (AUClast), estimated using the linear trapezoidal method.</description>
        <time_frame>Days 1, 10, 22, 36, 50, 78 and 106</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>Participants received a single subcutaneous injection of 60 mg denosumab on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Denosumab in Serum</title>
          <description>The area under the denosumab serum concentration-time curve from time zero to last quantifiable concentration (AUClast), estimated using the linear trapezoidal method.</description>
          <population>Pharmacokinetic population</population>
          <units>days*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333000" spread="122000" lower_limit="8.0" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Maximum Seminal Fluid Concentration by the Serum Concentration (Cmax Ratio)</title>
        <description>The ratio of maximum denosumab seminal fluid concentration over the denosumab serum concentration at the corresponding time point (Cmax Ratio)</description>
        <time_frame>Days 1, 10, 22, 36, 50, 78 and 106</time_frame>
        <population>Pharmacokinetic population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>Participants received a single subcutaneous injection of 60 mg denosumab on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Maximum Seminal Fluid Concentration by the Serum Concentration (Cmax Ratio)</title>
          <description>The ratio of maximum denosumab seminal fluid concentration over the denosumab serum concentration at the corresponding time point (Cmax Ratio)</description>
          <population>Pharmacokinetic population with available data</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0217" spread="0.0154" lower_limit="8.0" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Seminal Fluid AUC by Serum AUC for the 106 Day Dosing Period</title>
        <description>The ratio of denosumab seminal fluid AUC over denosumab serum AUC for the 106-day dosing period.</description>
        <time_frame>Days 1, 10, 22, 36, 50, 78 and 106</time_frame>
        <population>Pharmacokinetic population</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>Participants received a single subcutaneous injection of 60 mg denosumab on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Seminal Fluid AUC by Serum AUC for the 106 Day Dosing Period</title>
          <description>The ratio of denosumab seminal fluid AUC over denosumab serum AUC for the 106-day dosing period.</description>
          <population>Pharmacokinetic population</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0170" spread="0.0148" lower_limit="8.0" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio of Denosumab Seminal Fluid Concentration Over the Denosumab Serum Concentration at the Last Study Time Point (Day 106).</title>
        <time_frame>Day 106</time_frame>
        <population>Pharmacokinetic population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Denosumab</title>
            <description>Participants received a single subcutaneous injection of 60 mg denosumab on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio of Denosumab Seminal Fluid Concentration Over the Denosumab Serum Concentration at the Last Study Time Point (Day 106).</title>
          <population>Pharmacokinetic population with available data</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0197" spread="0.0318" lower_limit="8.0" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>78 days</time_frame>
      <desc>Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Denosumab 60 mg SC</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

